Beam Therapeutics ( (BEAM) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Beam Therapeutics shares are sliding as traders lock in profits after a recent post-earnings rally and react to a classic “sell the news” move. The pressure is intensified by the stock’s removal from the Russell 3000 Value and Russell Small Cap Complementary Value indices, which appears to have sparked institutional selling.
Investor mood is also dampened by cautious positioning ahead of upcoming clinical presentations at the RBC Capital Markets Global Healthcare Conference. While H.C. Wainwright reaffirmed its Buy rating, Bernstein trimmed its price target on May 13, adding to the negative tone around the stock.
More about Beam Therapeutics
YTD Price Performance: 14.90%
Average Trading Volume: 2,094,777
Technical Sentiment Signal: Buy
Current Market Cap: $3.25B
For further insights into BEAM stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.